Dizal Pharmaceutical's Hong Kong IPO Prospectus Lapses

Stock News

Yesterday

The Hong Kong IPO prospectus submitted by Dizal Pharmaceutical Co.,Ltd. (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai International were the joint sponsors at the time of filing.

According to the prospectus, Dizal Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases. Its marketed product, Sunvozertinib®, is the only small-molecule epidermal growth factor receptor tyrosine kinase inhibitor globally approved for treating non-small cell lung cancer with EGFR exon 20 insertion mutations.

For the fiscal year 2023, the fiscal year 2024, and the nine months ended September 30, 2025, the company reported revenues of approximately RMB 91.3 million, RMB 360 million, and RMB 586 million, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1159047255"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159047255\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159047255?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-23 10:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159047255","market":"us","top_or_hot":-1,"title":"Dizal Pharmaceutical's Hong Kong IPO Prospectus Lapses","media":"Stock News","content":"<p>The Hong Kong IPO prospectus submitted by <b>Dizal Pharmaceutical Co.,Ltd.</b> (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai International were the joint sponsors at the time of filing.<br><br>According to the prospectus, Dizal Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases. Its marketed product, Sunvozertinib®, is the only small-molecule epidermal growth factor receptor tyrosine kinase inhibitor globally approved for treating non-small cell lung cancer with EGFR exon 20 insertion mutations.<br><br>For the fiscal year 2023, the fiscal year 2024, and the nine months ended September 30, 2025, the company reported revenues of approximately RMB 91.3 million, RMB 360 million, and RMB 586 million, respectively.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dizal Pharmaceutical's Hong Kong IPO Prospectus Lapses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDizal Pharmaceutical's Hong Kong IPO Prospectus Lapses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-23 10:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The Hong Kong IPO prospectus submitted by <b>Dizal Pharmaceutical Co.,Ltd.</b> (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai International were the joint sponsors at the time of filing.<br><br>According to the prospectus, Dizal Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases. Its marketed product, Sunvozertinib®, is the only small-molecule epidermal growth factor receptor tyrosine kinase inhibitor globally approved for treating non-small cell lung cancer with EGFR exon 20 insertion mutations.<br><br>For the fiscal year 2023, the fiscal year 2024, and the nine months ended September 30, 2025, the company reported revenues of approximately RMB 91.3 million, RMB 360 million, and RMB 586 million, respectively.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REDS","symbol_name":"RPM Republican Senate ETF","start_time":0,"source_url":"","article_id":"1159047255","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159047255","pubTimestamp":1784775187,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The Hong Kong IPO prospectus submitted by Dizal Pharmaceutical Co.,Ltd. (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","688192":"迪哲医药-U","REDS":"RPM Republican Senate ETF","BK1515":"抗疫概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","FRHC":"Euronext CAC Health Care","09939":"开拓药业-B","BK1574":"生物医药B类股","BK4127":"投资银行业与经纪业","IPOS":"Renaissance International IPO ETF","BK0239":"医药制造","KCE":"SPDR KBW Capital Markets ETF","VXUS":"国际股票ETF-Vanguard","KCAI":"KraneShares China Alpha Index ETF"},"translate_title":"迪扎尔制药香港IPO招股说明书失效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"688192":1,"REDS":1,"IPOS":1,"KCAI":1,"VXUS":1,"FRHC":1,"09939":1,"KCE":1},"content_text":"The Hong Kong IPO prospectus submitted by Dizal Pharmaceutical Co.,Ltd. (688192.SH) on January 23, 2026, has lapsed as of July 23, 2026, after being active for six months. Goldman Sachs and Huatai International were the joint sponsors at the time of filing.According to the prospectus, Dizal Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases. Its marketed product, Sunvozertinib®, is the only small-molecule epidermal growth factor receptor tyrosine kinase inhibitor globally approved for treating non-small cell lung cancer with EGFR exon 20 insertion mutations.For the fiscal year 2023, the fiscal year 2024, and the nine months ended September 30, 2025, the company reported revenues of approximately RMB 91.3 million, RMB 360 million, and RMB 586 million, respectively.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}